JAK/TYK2

Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. As a small sample of novel agents demonstrating efficacy in PsA presented at ACR Convergence 2021, we have…

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.  Gender and…

Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis. With…

Still's disease is an autoinflammatory disease characterized by spiking fever, rash, polyarthralgia, sore throat and even life-threatening complications, such as macrophage activation syndrome. It…

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and…

Growing awareness of spondyloarthropathies over the last two decades has inevitably led to a better understanding of the pathophysiology of spondyloarthritis (SpA), and subsequently increased…

Giant cell arteritis (GCA) is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. We will hopefully see an impact on this due to…

The COVID-19 pandemic has presented a global challenge. Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections. Over the past…